

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on Apr 24, 2025

Olink Bioscience

RRID:SCR_003899

Type: Tool

Proper Citation

Olink Bioscience (RRID:SCR_003899)

Resource Information

URL: <http://www.olink.com/>

Proper Citation: Olink Bioscience (RRID:SCR_003899)

Description: Commercial organization that produces products for biomarker research and development. Their goal is to help customers and collaborators to improve clinical decisions through the use of molecular biomarkers. Their tools bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology.

Abbreviations: Olink

Resource Type: commercial organization

Keywords: biomarker, disease

Funding:

Resource Name: Olink Bioscience

Resource ID: SCR_003899

Alternate IDs: nlx_158232

Record Creation Time: 20220129T080221+0000

Record Last Update: 20250420T014157+0000

Ratings and Alerts

No rating or validation information has been found for Olink Bioscience.

No alerts have been found for Olink Bioscience.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 218 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

McGarry A, et al. (2025) A Pilot Proteomic Analysis of Huntington's Disease by Functional Capacity. *Brain sciences*, 15(1).

Gonzalez-Kozlova E, et al. (2024) Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma. *Cancer research communications*, 4(7), 1726.

Bessede A, et al. (2024) TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(4), 779.

Kong T, et al. (2024) Identification of novel protein biomarkers from the blood and urine for the early diagnosis of bladder cancer via proximity extension analysis. *Journal of translational medicine*, 22(1), 314.

Lehrer S, et al. (2024) Long-lasting cigarette smoking alterations in immune function occur in cannabis smokers, possibly rendering them vulnerable to smoking-related tumors in later life. *medRxiv : the preprint server for health sciences*.

Zhang X, et al. (2024) Targeted proteomics-determined multi-biomarker profiles developed classifier for prognosis and immunotherapy responses of advanced cervical cancer. *Frontiers in immunology*, 15, 1391524.

Næss M, et al. (2024) Data Resource Profile: The HUNT Biobank. *International journal of epidemiology*, 53(3).

Hedlund Lindberg J, et al. (2024) Toward ovarian cancer screening with protein biomarkers using dried, self-sampled cervico-vaginal fluid. *iScience*, 27(2), 109001.

Ahamed MT, et al. (2024) Multiplex plasma protein assays as a diagnostic tool for lung cancer. *Cancer science*, 115(10), 3439.

Wu J, et al. (2024) Nivolumab plus anlotinib hydrochloride in advanced gastric

adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial. *Nature communications*, 15(1), 8876.

Sarin KY, et al. (2024) Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus. *JCI insight*, 9(5).

Baghdadi M, et al. (2024) Intermittent rapamycin feeding recapitulates some effects of continuous treatment while maintaining lifespan extension. *Molecular metabolism*, 81, 101902.

Kalnapenkis A, et al. (2024) Genetic determinants of plasma protein levels in the Estonian population. *Scientific reports*, 14(1), 7694.

Gao M, et al. (2024) Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer. *Journal for immunotherapy of cancer*, 12(2).

Dimitriou F, et al. (2024) A targetable type III immune response with increase of IL-17A expressing CD4+ T[?] cells is associated with immunotherapy-induced toxicity in melanoma. *Nature cancer*, 5(9), 1390.

Xu X, et al. (2024) Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study. *Nature communications*, 15(1), 7255.

Lovre D, et al. (2024) Acute estradiol and progesterone therapy in hospitalized adults to reduce COVID-19 severity: a randomized control trial. *Scientific reports*, 14(1), 22732.

Guibinga GH, et al. (2024) Comparative assessment of the transduction efficiency and safety associated with the delivery of AAV9-GFP vector via lumbar puncture to cynomolgus macaques with and without anti-AAV9 pre-existing antibodies. *Molecular therapy. Methods & clinical development*, 32(4), 101371.

Reus LM, et al. (2024) Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia. *Brain : a journal of neurology*, 147(10), 3522.

Glitza IC, et al. (2024) Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. *Cancer discovery*, 14(7), 1161.